Sonoma Pharmaceuticals Financials

SNOA Stock  USD 2.50  0.01  0.40%   
Based on the key indicators related to Sonoma Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Sonoma Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in March. At present, Sonoma Pharmaceuticals' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Cash is expected to grow to about 5.3 M, whereas Total Assets are forecasted to decline to about 15.3 M. Key indicators impacting Sonoma Pharmaceuticals' financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Current Ratio2.333.04
Way Down
Pretty Stable
The essential information of the day-to-day investment outlook for Sonoma Pharmaceuticals includes many different criteria found on its balance sheet. An individual investor should monitor Sonoma Pharmaceuticals' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Sonoma Pharmaceuticals.

Net Income

(5.84 Million)

-11.8M-2.9M-4.6M-5.1M-5.2M-4.8M-5.6M-5.8M100%
  

Sonoma Pharmaceuticals Earnings Geography

Please note, the presentation of Sonoma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sonoma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sonoma Pharmaceuticals' management manipulating its earnings.

Sonoma Pharmaceuticals Stock Summary

Sonoma Pharmaceuticals competes with China Pharma, Universe Pharmaceuticals, Akanda Corp, Petros Pharmaceuticals, and Sunshine Biopharma. Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia. Sonoma Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
ISINUS83558L2043
CUSIP67575P207 83558L105 83558L204 67575P306 83558L303 67575P108
LocationCalifornia; U.S.A
Business Address5445 Conestoga Court,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitesonomapharma.com
Phone800 759 9305
CurrencyUSD - US Dollar

Sonoma Pharmaceuticals Key Financial Ratios

Sonoma Pharmaceuticals Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets15.0M18.8M16.2M14.7M17.0M15.3M
Net Debt(1.5M)(6.0M)(3.0M)(2.5M)(2.3M)(2.4M)
Cash4.2M7.4M3.8M3.1M2.8M5.3M
Total Current Assets13.0M16.4M13.8M12.5M14.4M12.6M
Other Assets850K875K1.5M1.5M1.8M1.8M
Total Liab9.6M10.1M8.3M8.6M9.9M6.9M
Other Current Liab(2.6M)(2.0M)(2.5M)(2.8M)(2.5M)(2.4M)
Retained Earnings(179.3M)(184.4M)(189.5M)(194.3M)(174.9M)(183.7M)
Accounts Payable1.8M1.6M841K607K546.3K519.0K
Net Receivables2.8M2.4M2.6M2.9M3.3M2.3M
Inventory2.5M2.7M2.9M2.7M3.1M1.7M
Other Current Assets3.4M4.0M4.5M3.8M4.4M4.6M
Short Term Debt1.1M1.1M943K719K647.1K781.0K
Other Liab245K3.7M4.0M4.4M5.0M5.3M
Net Tangible Assets8.7M5.4M8.7M8.0M7.2M9.0M
Short Long Term Debt596K808K431K323K371.5K366.2K
Net Invested Capital7.3M9.5M8.4M6.5M5.8M7.7M

Sonoma Pharmaceuticals Key Income Statement Accounts

202020212022202320242025 (projected)
Interest Expense33K16K12K10K14.4K13.7K
Total Revenue18.6M12.6M13.3M12.7M14.6M11.3M
Gross Profit6.6M4.0M4.5M4.7M5.5M5.1M
Operating Income(3.4M)(5.9M)(4.6M)(4.7M)(5.4M)(5.7M)
Ebit(3.4M)(6.1M)(4.7M)(4.7M)(5.4M)(5.7M)
Research Development555K125K207K1.9M1.7M1.7M
Ebitda(3.2M)(5.7M)(4.4M)(4.5M)(5.2M)(5.5M)
Cost Of Revenue12.1M8.6M8.8M8.0M9.2M6.5M
Income Before Tax(3.9M)(5.4M)(5.2M)(5.0M)(5.8M)(6.1M)
Net Income(4.6M)(5.1M)(5.2M)(4.8M)(5.6M)(5.8M)
Income Tax Expense713K(332K)(33K)(196K)(176.4K)(167.6K)
Tax Provision713K(332K)(33K)(196K)(225.4K)(236.7K)
Net Interest Income34K4K(10K)16K14.4K13.7K

Sonoma Pharmaceuticals Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash529K3.2M(3.6M)(692K)(622.8K)(591.7K)
Free Cash Flow(3.6M)(4.4M)(6.4M)(2.4M)(2.8M)(2.9M)
Depreciation227K186K125K176K158.4K298.9K
Other Non Cash Items4K(2.0M)106K161K144.9K152.1K
Capital Expenditures179K137K269K17K15.3K14.5K
Net Income(4.0M)(5.1M)(5.2M)(4.8M)(5.6M)(5.8M)
End Period Cash Flow4.2M7.4M3.8M3.1M2.8M2.7M
Change To Inventory(65K)(100K)44K184K211.6K222.2K
Investments388K(99K)(258K)(2K)(1.8K)(1.7K)
Net Borrowings(347K)1.0M(374K)(379K)(435.9K)(457.6K)
Change To Netincome(1.2M)(1.0M)(2.5M)738K848.7K891.1K

Sonoma Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Sonoma Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Sonoma Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sonoma Pharmaceuticals competition to find correlations between indicators driving Sonoma Pharmaceuticals's intrinsic value. More Info.
JavaScript chart by amCharts 3.21.15SXTCSGIOYGSACLOVFFUNRVGHSISNOA -3.5-3.0-2.5-2.0-1.5-1.0-0.50 -3.0-2.5-2.0-1.5-1.0-0.50
Sonoma Pharmaceuticals is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Sonoma Pharmaceuticals' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sonoma Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Sonoma Pharmaceuticals' Earnings Breakdown by Geography

Sonoma Pharmaceuticals Systematic Risk

Sonoma Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sonoma Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Sonoma Pharmaceuticals correlated with the market. If Beta is less than 0 Sonoma Pharmaceuticals generally moves in the opposite direction as compared to the market. If Sonoma Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sonoma Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sonoma Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Sonoma Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
JavaScript chart by amCharts 3.21.15Dec2025FebJanJan 13Jan 20Jan 27FebFeb 10Feb 172.502.552.602.652.702.752.80 50K100K150K200K250K -0.0500.050.100.150.20 42K42.5K43K43.5K44K44.5K Show all
JavaScript chart by amCharts 3.21.15Sonoma Pharmaceuticals Volume Sonoma Pharmaceuticals Closing Prices Dow Jones Industrial Closing Prices - Benchmark Sonoma Pharmaceuticals Beta
Today, most investors in Sonoma Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sonoma Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Sonoma Pharmaceuticals growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.009676

-0.002-0.077-0.0810.02350.0596-1.150.220.06180.0080.01020.009100%
At present, Sonoma Pharmaceuticals' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.

Sonoma Pharmaceuticals February 19, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Sonoma Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sonoma Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sonoma Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Sonoma Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sonoma Pharmaceuticals's daily price indicators and compare them against related drivers.

Complementary Tools for Sonoma Stock analysis

When running Sonoma Pharmaceuticals' price analysis, check to measure Sonoma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sonoma Pharmaceuticals is operating at the current time. Most of Sonoma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Sonoma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sonoma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Sonoma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Bonds Directory
Find actively traded corporate debentures issued by US companies
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators

Trending Assets

MSMY
Mc Endvrs
0  0.0002  25.00 
AKAN
Akanda Corp
1.74  -0.02  -1.14 
SXTC
China SXT Pharmaceuticals
0.38  -0.01  -2.56 
UNRV
Unrivaled Brands
0.00  0.00  0.00